Report Type : Industry Trends
Report Category : Research Insights
Report Subcategory : Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T)
Price : 1999.00
Date : October 2024
Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) : Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing
Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T):
CAR-T is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer.
Key Players:
